What is the AI rating for ADXN?

Addex Therapeutics Ltd. (ADXN) has an AI rating of HOLD with 15% confidence, based on fundamental analysis of SEC EDGAR filings.

What are the key strengths of ADXN?

Listed on Nasdaq indicating regulatory compliance and market access

What are the risks of investing in ADXN?

Complete absence of revenue and profitability data prevents assessment of business viability. No balance sheet metrics available to evaluate financial stability or liquidity. Inability to determine if company is pre-revenue, in development stage, or experiencing reporting issues

What is ADXN's revenue growth rate?

Addex Therapeutics Ltd. (ADXN) has a revenue growth rate of N/A year-over-year, based on the latest SEC EDGAR filings.

Does ADXN pay dividends?

Addex Therapeutics Ltd. (ADXN) does not currently pay dividends.

Where can I find ADXN SEC filings?

Official SEC filings for Addex Therapeutics Ltd. (CIK: 0001574232) including 10-K annual reports, 10-Q quarterly reports, and 8-K current reports are available on SEC EDGAR at sec.gov.

What is ADXN's EPS growth?

Addex Therapeutics Ltd. earnings per share (EPS) growth is N/A year-over-year. Current diluted EPS is $0.00.

ADXN Stock Analysis - Addex Therapeutics Ltd. AI Rating & Fundamentals

Name: Addex Therapeutics Ltd. (ADXN) Stock
Brand: Addex Therapeutics Ltd.
Rating: 3 (1 reviews)

Investment Thesis

Insufficient financial data available for meaningful fundamental analysis. Unable to assess profitability, financial health, or operational trends due to lack of reported metrics across income statement, balance sheet, and cash flow statements.

ADXN Strengths

+ Listed on Nasdaq indicating regulatory compliance and market access

ADXN Risks

! Complete absence of revenue and profitability data prevents assessment of business viability
! No balance sheet metrics available to evaluate financial stability or liquidity
! Inability to determine if company is pre-revenue, in development stage, or experiencing reporting issues
! No cash flow data to assess burn rate or operational sustainability
! Zero insider activity in last 90 days suggests lack of insider confidence or dormancy

Key Metrics to Watch

* Revenue generation and gross margins once available
* Operating cash flow and cash position relative to burn rate
* Pipeline progress and clinical trial results for therapeutic candidates

ADXN Financial Metrics

Revenue

N/A

Net Income

N/A

EPS (Diluted)

$0.00

Free Cash Flow

N/A

Total Assets

N/A

Cash Position

N/A

ADXN Profitability Ratios

Gross Margin N/A

Operating Margin N/A

Net Margin N/A

ROE N/A

ROA N/A

FCF Margin N/A

ADXN Balance Sheet & Liquidity

Current Ratio

N/A

Quick Ratio

N/A

Debt/Equity

N/A

Debt/Assets

0.0%

Interest Coverage

N/A

Long-term Debt

N/A

ADXN Growth Metrics (YoY)

Revenue Growth

N/A

Year-over-year

Net Income Growth

N/A

Year-over-year

EPS Growth

N/A

Earnings per share

FCF Margin

N/A

Free cash flow / Revenue

ADXN SEC Filings

Access official SEC EDGAR filings for Addex Therapeutics Ltd. (CIK: 0001574232)

📄 10-K Annual Reports 📋 10-Q Quarterly Reports 📰 8-K Current Reports 📊 Proxy Statements 🔍 All Filings

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.

Data Source: SEC EDGAR | Analysis Date: Mar 19, 2026 | Data as of: 2026-03-19 | Powered by Claude AI